Professor JianHui Tian, MD, Shanghai University of Traditional Chinese Medicine, China
Jia Xu, PhD, The University of Alabama at Birmingham, United States
Biological Procedures Online is calling for submissions to our Collection on Cancer Therapy and Immunotherapy: Challenges and Opportunities.
Image credit: © wildpixel / Getty Images / iStock
Professor JianHui Tian, MD, Shanghai University of Traditional Chinese Medicine, China
Prof. JianHui Tian is a leading oncologist specializing in the integration of Traditional Chinese Medicine (TCM) and Western medicine. With over 25 years of experience, Dr. Tian has made significant contributions to the clinical and basic research on cancer treatment, focusing on lung cancer, gynecological cancers, and breast cancer. Under the mentorship of Prof. Liu JiaXiang, a National Master of TCM, Dr. Tian has advanced the academic thought of “Strengthening Health Qi to Treat Cancer” and has integrated this philosophy into national and international cancer treatment protocols.
Dr. Tian is recognized for pioneering the world's first human lung cancer circulating tumor cell line (CTC-TJH-01) and establishing a CTC-based organoid culture and metastasis research platform. These innovations have enhanced the understanding of lung cancer metastasis and improved the accuracy of clinical evaluations in China. Over the years, he has published more than 200 research papers, with over 40 papers indexed by SCI, and has been granted six patents related to cancer treatment and diagnostics.
Research and Innovation
Dr. Tian's research focuses on the immune regulation of lung cancer, particularly the mechanisms of tumor microenvironment interaction. He developed the theory of “Zheng Deficiency and Hidden Poison”, which explains the core pathogenesis of lung cancer and its metastasis. His work has improved prognostic models and precision treatment approaches for lung cancer patients in China. His recent research explores the use of NK cell-induced tumor dormancy and the role of immune senescence in preventing metastasis.
Dr. Tian has secured several national and municipal grants, including funding from the National Natural Science Foundation of China for projects on lung cancer metastasis and immune regulation. He has also been awarded multiple first prizes in the field of TCM oncology and received the Scientific and Technological Progress Award from the Shanghai Municipal People’s Government.
Significant advances have been made in cancer therapy and immunotherapy, including the development of targeted antineoplastic agents, robust tumor cell lines and xenograft models for drug screening, and the exploration of immunological approaches to cancer inhibition. These breakthroughs have provided valuable insights into drug resistance, tumor biology, and the interplay between the immune system and cancer cells. They have also paved the way for innovative immunotherapeutic interventions, such as immune checkpoint inhibitors and CAR T-cell therapy, revolutionizing cancer treatment paradigms.
Future research may focus on unraveling the molecular mechanisms underlying drug resistance, refining xenograft models and antitumor assays, and identifying novel immunotherapeutic targets for enhanced treatment efficacy. Cutting-edge technologies, such as single-cell sequencing and advanced imaging modalities, are poised to provide unprecedented insights into tumor heterogeneity, immune cell dynamics, and the tumor microenvironment, shaping the next generation of cancer therapies.
This Collection seeks to showcase cutting-edge research in cancer therapy and immunotherapy, focusing on the challenges and opportunities in the development of novel treatment strategies, the exploration of immunological approaches, and the understanding of drug resistance mechanisms. We welcome multidisciplinary approaches integrating novel methodologies from medicine, biology, imaging, engineering, bioinformatics, and system analysis.
There are currently no articles in this collection.
This Collection welcomes submission of original research and review articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal.
Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Cancer Therapy and Immunotherapy: Challenges and Opportunities" under the “Details” tab during the submission stage.
Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.
The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.